Associated Papers
Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.
Cheung CH et al.
Plos One, 2010
Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
Wiesen KM et al.
Cancer Letters, 2007
Do beta-tubulin mutations have a role in resistance to chemotherapy?
Berrieman HK et al.
The Lancet. Oncology, 2004
Select a paper to view details